Literature DB >> 31678864

A likely protective effect of dimethyl itaconate on cerebral ischemia/reperfusion injury.

Di Zhang1, Zhengfang Lu1, Zhen Zhang1, Jiang Man1, Ruiming Guo2, Chang Liu1, Jianping Wang3.   

Abstract

As a membrane-permeable derivative of itaconate, dimethyl itaconate (DMI) was recently showed to limit inflammatory response of activated macrophages, and to decrease the generation of reactive oxygen species and reduce cardiac ischemia/reperfusion injury. However, the effect of DMI in the context of cerebral ischemia/reperfusion injury remains unclear. Here, we treated the transient middle cerebral artery occlusion (tMCAO) mice with DMI or saline at the beginning of occlusion, and allowed them to recover for 3 days. We found that DMI obviously decreased the neurologic deficit score. Further, DMI significantly inhibited the toxic conversion of the peri-infarct microglia, and decreased the protein level of interleukin 1β. The present findings suggest that DMI might be recognized as a promising candidate for the treatment of ischemic stroke.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cerebral ischemia/reperfusion injury; Dimethyl itaconate; Microglia

Mesh:

Substances:

Year:  2019        PMID: 31678864     DOI: 10.1016/j.intimp.2019.105924

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  7 in total

1.  Dimethyl Itaconate Reduces Cognitive Impairment and Neuroinflammation in APPswe/PS1ΔE9 Transgenic Mouse Model of Alzheimer's Disease.

Authors:  Jing Xiong; Dong-Lin Lu; Bai-Qiang Chen; Tong-Yun Liu; Zi-Xuan Wang
Journal:  Neuromolecular Med       Date:  2022-08-08       Impact factor: 4.103

Review 2.  The Emerging Application of Itaconate: Promising Molecular Targets and Therapeutic Opportunities.

Authors:  Jiaqi Lin; Jinxuan Ren; Dave Schwinn Gao; Yi Dai; Lina Yu
Journal:  Front Chem       Date:  2021-05-12       Impact factor: 5.221

3.  Establishment, Validation, and Initial Application of a Sensitive LC-MS/MS Assay for Quantification of the Naturally Occurring Isomers Itaconate, Mesaconate, and Citraconate.

Authors:  Moritz Winterhoff; Fangfang Chen; Nishika Sahini; Thomas Ebensen; Maike Kuhn; Volkhard Kaever; Heike Bähre; Frank Pessler
Journal:  Metabolites       Date:  2021-04-26

4.  Aconitate decarboxylase 1 suppresses cerebral ischemia-reperfusion injury in mice.

Authors:  Thomas M Vigil; Ryan A Frieler; KiAundra L Kilpatrick; Michael M Wang; Richard M Mortensen
Journal:  Exp Neurol       Date:  2021-10-23       Impact factor: 5.330

Review 5.  Itaconate as an inflammatory mediator and therapeutic target in cardiovascular medicine.

Authors:  Marina Diotallevi; Faseeha Ayaz; Thomas Nicol; Mark J Crabtree
Journal:  Biochem Soc Trans       Date:  2021-11-01       Impact factor: 5.407

6.  Itaconate and Its Derivatives Repress Early Myogenesis In Vitro and In Vivo.

Authors:  Tae Seok Oh; Damian C Hutchins; Rabina Mainali; Kevin H Goslen; Matthew A Quinn
Journal:  Front Immunol       Date:  2022-02-21       Impact factor: 7.561

7.  Aconitate decarboxylase 1 regulates glucose homeostasis and obesity in mice.

Authors:  Ryan A Frieler; Thomas M Vigil; Jianrui Song; Christy Leung; Daniel R Goldstein; Carey N Lumeng; Richard M Mortensen
Journal:  Obesity (Silver Spring)       Date:  2022-08-04       Impact factor: 9.298

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.